Since 1971, the landscape of drug research in the United States has been drastically altered, with severe restrictions placed on the study of substances deemed “most dangerous.” The Controlled Substances Act (CSA), ostensibly implemented for public protection, has instead created a system that inadvertently benefits pharmaceutical companies by maintaining their monopoly on drug manufacturing and distribution.
Germany has received nearly 900 applications for cannabis cultivation associations, but only just over half…
A Senate stopgap funding bill would delay the federal prohibition on most hemp-derived THC products…
He smokes in boardrooms, but he’s still on that underground frequency. This content originally appeared…
Fox News opinion ran a piece recently from Scott Chipman, vice president of Americans Against…
For our 50th anniversary, we handed the plant to the artists making its most striking…
Corporate valuation increased in 21 of the 38 states studied following medical marijuana legalization. Gross…